Hymecromone clinical trial is cautiously positive
- Robyn Kalda
- Jul 7
- 1 min read
A very small (16 patients) phase 2a clinical trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD) looked at whether hymecromone, a drug that might help blood vessels, had any promising effects.
Overall, the results weren't statistically significant, but half the patients treated with hymecromone improved their six-minute walk distance by 66m and had improved quality of life. Researchers concluded that a larger trial is warranted.
Comentários